{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:52:43Z","timestamp":1784011963039,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xiefeng Yang","award":["2018QH1075,2021QNB006"],"award-info":[{"award-number":["2018QH1075,2021QNB006"]}]},{"name":"Dairong Cao","award":["2019-CX-23, 2019-WJ-10, 2020Y0025, 82071869"],"award-info":[{"award-number":["2019-CX-23, 2019-WJ-10, 2020Y0025, 82071869"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The accurate grading of IDH-mutant astrocytoma is essential to make therapeutic strategies and assess the prognosis of patients. The purpose of this study was to investigate the usefulness of DWI, SWI and DSC-PWI in grading IDH-mutant astrocytoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred and seven patients with IDH-mutant astrocytoma who underwent DWI, SWI and DSC-PWI were retrospectively reviewed. Minimum apparent diffusion coefficient (ADC<jats:sub>min<\/jats:sub>), intratumoral susceptibility signal intensity(ITSS) and maximum relative cerebral blood volume (rCBV<jats:sub>max<\/jats:sub>) values were assessed. ADC<jats:sub>min<\/jats:sub>, ITSS and rCBV<jats:sub>max<\/jats:sub> values were compared between grade 2 vs. grade 3, grade 3 vs. grade 4 and grade 2\u2009+\u20093 vs. grade 4 tumors. Logistic regression, tenfold cross-validation,and receiver operating characteristic (ROC) curve analyses were used to assess their diagnostic performances.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Grade 4 IDH-mutant astrocytomas showed significantly lower ADC<jats:sub>min<\/jats:sub> and higher rCBV<jats:sub>max<\/jats:sub> as compared to grade 3 tumors (adjusted <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). IDH-mutant grade 3 astrocytomas showed significantly lower ITSS levels as compared with grade 4 tumors (adjusted <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). ITSS levels between IDH-mutant grade 2 and grade 3 astrocytomas were significantly different (adjusted <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Combined the ADC<jats:sub>min<\/jats:sub>, ITSS and rCBV<jats:sub>max<\/jats:sub> resulted in the highest AUC for differentiation grade 2 and grade 3 tumors from grade 4 tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ADC<jats:sub>min,<\/jats:sub> rCBV<jats:sub>max<\/jats:sub> and ITSS can be used for grading the IDH-mutant astrocytomas. The combination of ADC<jats:sub>min,<\/jats:sub> ITSS and rCBV<jats:sub>max<\/jats:sub> could improve the diagnostic performance in grading of IDH-mutant astrocytoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-022-00832-3","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T12:02:48Z","timestamp":1653825768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiefeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dairong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"key":"832_CR1","first-page":"23","volume":"2021","author":"D Louis","year":"2021","unstructured":"Louis D, Perry A, Wesseling P, The, et al. WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;2021:23.","journal-title":"Neuro Oncol"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","volume":"136","author":"M Shirahata","year":"2018","unstructured":"Shirahata M, Ono T, Stichel D, et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 2018;136:153\u201366.","journal-title":"Acta Neuropathol"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10014-018-0309-0","volume":"35","author":"T Iuchi","year":"2018","unstructured":"Iuchi T, Sugiyama T, Ohira M, et al. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Brain Tumor Pathol. 2018;35:71\u201380.","journal-title":"Brain Tumor Pathol"},{"key":"832_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Den Bent MJV, Tonn JC, et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:315\u201329.","journal-title":"Lancet Oncol"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrn1119","volume":"4","author":"D Le Bihan","year":"2003","unstructured":"Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci. 2003;4:469\u201380.","journal-title":"Nat Rev Neurosci"},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2214\/ajr.179.3.1790783","volume":"179","author":"JH Shin","year":"2002","unstructured":"Shin JH, Lee HK, Kwun BD, et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol. 2002;179:783\u20139.","journal-title":"Am J Roentgenol"},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3174\/ajnr.A1593","volume":"30","author":"MJ Park","year":"2009","unstructured":"Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. Am J Neuroradiol. 2009;30:1402\u20138.","journal-title":"Am J Neuroradiol"},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11060-017-2506-9","volume":"134","author":"K Leu","year":"2017","unstructured":"Leu K, Ott GA, Lai A, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017;134:177\u201388.","journal-title":"J Neurooncol"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/jmri.24312","volume":"39","author":"XC Wang","year":"2014","unstructured":"Wang XC, Zhang H, Tan Y, et al. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas. J Mag Reson Imag JMRI. 2014;39:1569\u201374.","journal-title":"J Mag Reson Imag JMRI"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00234-017-1942-8","volume":"60","author":"J Saini","year":"2018","unstructured":"Saini J, Gupta PK, Sahoo P, et al. Differentiation of grade II\/III and grade IV glioma by combining \u201cT1 contrast-enhanced brain perfusion imaging\u201d and susceptibility-weighted quantitative imaging. Neuroradiology. 2018;60:43\u201350.","journal-title":"Neuroradiology"},{"key":"832_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/jmri.26786","volume":"51","author":"R Bhattacharjee","year":"2020","unstructured":"Bhattacharjee R, Gupta RK, Patir R, Vaishya S, Ahlawat S, Singh A. Quantitative vs semiquantitative assessment of intratumoral susceptibility signals in patients with different grades of glioma. J Mag Reson Imag JMRI. 2020;51:225\u201333.","journal-title":"J Mag Reson Imag JMRI"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.mric.2016.06.005","volume":"24","author":"JL Boxerman","year":"2016","unstructured":"Boxerman JL, Shiroishi MS, Ellingson BM, Pope WB. Dynamic susceptibility contrast MR imaging in glioma. Magn Reson Imaging Clin N Am. 2016;24:649\u201370.","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1148\/radiol.2413051276","volume":"241","author":"S Higano","year":"2006","unstructured":"Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839\u201346.","journal-title":"Radiology"},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3174\/ajnr.A3803","volume":"35","author":"WL Tan","year":"2014","unstructured":"Tan WL, Huang WY, Yin B, Xiong J, Wu JS, Geng D. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. Am J Neuroradiol. 2014;35:920\u20137.","journal-title":"Am J Neuroradiol"},{"key":"832_CR16","first-page":"2763","volume":"18","author":"JB Qin","year":"2019","unstructured":"Qin JB, Zhang H, Wang XC, Tan Y, Wu X. Combination value of diffusion-weighted imaging and dynamic susceptibility contrast-enhanced MRI in astrocytoma grading and correlation with GFAP. Topoisomerase II\u03b1 and MGMT Oncol Lett. 2019;18:2763\u201370.","journal-title":"Topoisomerase II\u03b1 and MGMT Oncol Lett"},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481\u201398.","journal-title":"N Engl J Med"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","volume":"129","author":"A Olar","year":"2015","unstructured":"Olar A, Wani KM, Alfaro-Munoz KD, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129:585\u201396.","journal-title":"Acta Neuropathol"},{"key":"832_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00401-015-1438-8","volume":"129","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Mamatjan Y, Schrimpf D, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129:867\u201373.","journal-title":"Acta Neuropathol"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2214\/AJR.12.8679","volume":"200","author":"M Zulfiqar","year":"2013","unstructured":"Zulfiqar M, Yousem DM, Lai H. ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor?\u2013a meta-analysis. AJR Am J Roentgenol. 2013;200:624\u20139.","journal-title":"AJR Am J Roentgenol"},{"key":"832_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejrad.2008.11.005","volume":"73","author":"GB Caseiras","year":"2010","unstructured":"Caseiras GB, Chheang S, Babb J, et al. Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol. 2010;73:215\u201320.","journal-title":"Eur J Radiol"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3174\/ajnr.A2280","volume":"32","author":"R Jain","year":"2011","unstructured":"Jain R, Gutierrez JA, Narang J, et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. Am J Neuroradiol. 2011;32:388\u201394.","journal-title":"Am J Neuroradiol"},{"key":"832_CR23","first-page":"1989","volume":"24","author":"M Law","year":"2003","unstructured":"Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003;24:1989\u201398.","journal-title":"Am J Neuroradiol"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/jmri.24312","volume":"39","author":"X Wang","year":"2014","unstructured":"Wang X, Zhang H, Tan Y, et al. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing WHO grade for brain astrocytomas. J Magn Reson Imaging. 2014;39:1569\u201374.","journal-title":"J Magn Reson Imaging"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3174\/ajnr.A2846","volume":"33","author":"A Hilario","year":"2012","unstructured":"Hilario A, Ramos A, Pereznunez A, et al. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. Am J Neuroradiol. 2012;33:701\u20137.","journal-title":"Am J Neuroradiol"},{"key":"832_CR26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3174\/ajnr.A0586","volume":"28","author":"JM Lupo","year":"2007","unstructured":"Lupo JM, Cha S, Chang SM, Nelson SJ. Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma. Am J Neuroradiol. 2007;28:1455\u201361.","journal-title":"Am J Neuroradiol"},{"key":"832_CR27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1231677","volume":"339","author":"J Losman","year":"2013","unstructured":"Losman J, Looper RE, Koivunen P, et al. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621\u20135.","journal-title":"Science"},{"key":"832_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature10898","volume":"483","author":"P Koivunen","year":"2012","unstructured":"Koivunen P, Lee S, Duncan CG, et al. Transformation by the ( R )-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484\u20138.","journal-title":"Nature"},{"key":"832_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1148\/radiol.2472070898","volume":"247","author":"M Law","year":"2008","unstructured":"Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490\u20138.","journal-title":"Radiology"},{"key":"832_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11060-013-1298-9","volume":"116","author":"R Mangla","year":"2014","unstructured":"Mangla R, Ginat DT, Kamalian S, et al. Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. J Neurooncol. 2014;116:325\u201331.","journal-title":"J Neurooncol"},{"key":"832_CR31","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3174\/ajnr.A1593","volume":"30","author":"MJ Park","year":"2009","unstructured":"Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30:1402\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"key":"832_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12880-020-00450-x","volume":"20","author":"XW Kang","year":"2020","unstructured":"Kang XW, Xi YB, Liu TT, et al. Grading of Glioma: combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging. BMC Med Imaging. 2020;20:50.","journal-title":"BMC Med Imaging"},{"key":"832_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1148\/radiol.2243011014","volume":"224","author":"SG Wetzel","year":"2002","unstructured":"Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002;224:797\u2013803.","journal-title":"Radiology"},{"key":"832_CR34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/neuonc\/noaa141","volume":"22","author":"JL Boxerman","year":"2020","unstructured":"Boxerman JL, Quarles CC, Hu LS, et al. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020;22:1262\u201375.","journal-title":"Neuro Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-022-00832-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-022-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T12:03:05Z","timestamp":1653825785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-022-00832-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1186\/s12880-022-00832-3","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,29]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University, and the informed consent was waived due to the nature of the retrospective study. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}